BPC-157: the monograph

BPC-157 is a synthetic chain of 15 amino acids (sequence GEPPPGKPADDAGLV, molecular weight 1419.5 Da) ^39,1. It reproduces a fragment of a larger protein called BPC that researchers reported isolating from human gastric juice, and it was first characterized in the scientific literature in 1993 ²⁴.

The compound went into corporate drug development in Croatia in the 1990s under the codes PL-10, PLD-116, and PL 14736 (Pliva), aimed at inflammatory bowel disease ²⁵. That program never produced a published efficacy trial or an approved drug, and no medicines agency anywhere has approved BPC-157 for any use ^37,32. Today it circulates as a gray-market vial and capsule product marketed with claims that run far ahead of its evidence.

This monograph grades every claim by the species it was tested in. The one-sentence version of three decades of research: a large body of rodent and laboratory findings, three small uncontrolled human pilot studies, and zero published randomized human trials ^31,32.

Every chip below carries an evidence grade. Animal means rodent or rabbit data; in vitro means cell or tissue experiments; regulatory means an FDA, WADA, or registry record. None of these facts is supported by a completed randomized human trial.

BPC-157 is not FDA approved. It is sold for research use; no human efficacy has been established. A search of FDA's approved-drug database returns no BPC-157 product in any form ³⁷.

FDA has gone further than silence. Its compounding safety list states that compounded BPC-157 drugs "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization," and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans" ³⁴. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 (free base and acetate), nominated for ulcerative colitis; both nominations had been withdrawn by their nominators, but FDA elected to proceed, and its briefing document proposed that neither form be included on the 503A Bulks List, the list of substances pharmacies may legally compound ^35,36. The committee's advice is non-binding and rulemaking is pending, but the direction of FDA's own evaluation is on the record.

In sport, BPC-157 is explicitly named on the 2026 WADA Prohibited List under S0 (Non-Approved Substances), prohibited at all times, in and out of competition ⁴³. USADA repeats this in plain language: BPC-157 is prohibited under the S0 category ⁴⁴. Some published reviews state incorrectly that BPC-157 is no longer WADA-listed; the current list itself is the controlling document, and it names BPC-157.

Mechanism work comes from animal and cell studies, not human tissue. The best-replicated threads: BPC-157 increased expression and internalization of the VEGFR2 receptor and activated the VEGFR2-Akt-eNOS signaling pathway in vascular endothelial cells, and raised vessel density in chick membrane and tube-formation assays; the same paper reported faster blood-flow recovery in rat hind-limb ischemia ²⁰. In rat tendon fibroblasts it accelerated cell spreading and migration through FAK-paxillin phosphorylation ⁴ and upregulated growth hormone receptor expression at mRNA and protein level ⁵.

The originating research group also reports interactions with the nitric oxide system, early growth response gene 1 (egr-1) expression, and dopamine and serotonin systems across many rat models ^25,28. Independent reviewers describe these pathways as plausible but note the mechanism has not been confirmed in any human study ^31,29.

The table below is the core of this monograph: 23 primary research entries, each with the species or model, the reported dose and route, the duration, and the outcome as stated in the fetched source. The census: 15 rows in rats, 2 in mice, 1 in rabbits, 1 pharmacokinetic study in rats and dogs, 2 in vitro, 1 combined rat and human-cell study, and exactly 1 human entry, an uncontrolled retrospective case series ²³. Zero rows are randomized human trials.

For calibration: a 2025 systematic review by an independent orthopaedic group screened 544 BPC-157 articles and found that only 36 met inclusion criteria, of which 35 were preclinical and exactly 1 was clinical ³⁰. An independent 2019 review noted that the majority of studies used small rodent models and that only a handful of research groups have performed in-depth work on this peptide ²⁹. Consistently positive results reported mostly by one laboratory group, with limited independent replication, is a weaker evidence base than the raw study count suggests; the head-to-head study in 2026 by an unrelated group is a welcome exception ¹¹.

This is the research base behind the compound's reputation, and it is rodent and rabbit work. In rats with a transected Achilles tendon, daily BPC-157 (10 ug, 10 ng, or 10 pg per kg, intraperitoneal) was associated with higher load to failure, better Achilles functional index scores, and restored tendon integrity versus saline ¹. After surgical detachment of the Achilles from the calcaneus, it improved tendon-to-bone reattachment measures and counteracted the aggravation caused by the corticosteroid 6alpha-methylprednisolone ²; a 72-rat study reported improved early functional recovery with reduced myeloperoxidase activity and more new vessel formation ³. In the rat medial collateral ligament model, improvement was reported with intraperitoneal, topical cream, and per-oral dosing (0.16 ug per mL of drinking water) ⁶. Transected quadriceps muscle showed improved biomechanics and walking recovery over 72 days ⁷, crush-injured gastrocnemius improved macroscopically, microscopically, functionally, and by muscle enzyme markers ⁸, and corticosteroid-impaired muscle repair was restored ⁹. In rabbits, a segmental radius defect showed improved bone filling comparable to bone marrow or autologous cortical graft in several measures ¹⁰.

The single head-to-head peptide comparison, from an independent Turkish group in 2026: in 32 rats with Achilles transection, both BPC-157 (10 ug/kg/day) and TB-500 (60 ug/kg/day) were associated with better tendon architecture than controls, but only TB-500 reached statistical significance on maximum load to failure and total histology scores; BPC-157 trended lower without reaching significance on total scores, and combining the two added nothing ¹¹. One rat study is not a verdict, but it is a useful antidote to marketing that presents BPC-157 as uniformly superior.

None of these outcomes has been tested in a published randomized human trial. The first attempt, a 120-participant phase 2 hamstring-strain trial, began recruiting in 2026 ⁴⁰.

BPC-157 began as a gastric-protection candidate, and the GI animal literature is broad. An independent Parke-Davis team reported in 1995 that intraperitoneal BPC-15 dose-dependently reduced TNBS-induced colonic damage and myeloperoxidase activity in rats, while a single intracolonic dose did not ¹². The Zagreb group reported reduced gastric and intestinal lesions from indomethacin, aspirin, and diclofenac in rats, plus attenuated adjuvant arthritis ¹³, and frames BPC-157 broadly as counteracting NSAID toxicity across stomach, intestine, liver, and brain models ²⁶.

The human trail is thinner than the marketing implies. Group reviews state that BPC-157 (as PL 14736) was tested in a phase II clinical program for inflammatory bowel disease and describe it as safe in those trials, with LD1 not achieved in toxicology ²⁵; later reviews also mention ulcerative colitis and multiple sclerosis trials ²⁷. No results from any of those trials have ever been published in peer-reviewed form, and a 2026 independent review concluded there is no completed phase II clinical trial ³². FDA's July 2026 compounding review of BPC-157 evaluated it specifically for ulcerative colitis and still proposed against listing it ^35,36.

Beyond muscle and gut, rat and mouse models report: improved motor recovery and counteracted spinal cord changes after compression injury in rats ¹⁷; faster axonal regeneration and improved walking indices after sciatic nerve transection ¹⁸; closure of perforating corneal incisions with eye drops, with recovered corneal transparency ¹⁹; attenuated brain lesions and better early outcomes after traumatic brain injury in mice ¹⁶; reduced bleeding time and smaller platelet-count falls after amputation in rats given heparin, warfarin, or aspirin ²¹; improved skin repair in corticosteroid-impaired burned mice with a topical cream ¹⁴; and dose-dependent acceleration of excisional wound closure in hyperglycemic rats, comparable at top doses to becaplermin gel, in a study by PLIVA's own research institute ¹⁵.

The breadth is real, and so is the pattern: nearly every model, nearly every organ, nearly always a positive result. Independent reviewers read that uniformity as a reason for more rigorous confirmation, not less ^29,31.

No adequately powered randomized controlled trial of BPC-157 has been published for any indication as of August 2026. Total published human exposure across all studies is fewer than 30 subjects, in three uncontrolled pilot studies ³². That is the entire human efficacy record.

What the three pilots are: (1) a retrospective, uncontrolled phone-survey case series of intra-articular knee injections at a Florida clinic, 16 patients reached, in which 11 of 12 who got BPC-157 alone reported significant pain improvement and 14 of 16 overall reported relief; no imaging, no standardized instruments, no control group ²³; a 2025 systematic review reads the same data as 7 of 12 reporting relief lasting over six months ³⁰; (2) an interstitial cystitis pilot; and (3) an intravenous safety and pharmacokinetics pilot, reported with two subjects in the PK literature ^31,32.

Registry records add context but no results: a randomized phase 1 safety study of BPC-157 (as PCO-02) in 42 healthy volunteers was registered in 2015 and its status is now listed as unknown, with no posted results ⁴¹; a single-arm 40-person study of an oral BPC-157 gummy (500 ug per serving) completed in 2026 with no published results ⁴²; and the first randomized, quadruple-masked phase 2 trial, BPC-157 for acute grade II hamstring strain with MRI-verified endpoints, target n=120, is recruiting as of 2026 ⁴⁰. Until that class of trial reads out, every efficacy claim about BPC-157 in humans is an extrapolation from rodents.

There is no adequately characterized human pharmacokinetic study of BPC-157. The best PK data are preclinical: a 2022 ADME study in rats and beagle dogs found an elimination half-life under 30 minutes, linear kinetics across doses, intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, metabolism into small peptide fragments and then single amino acids, and excretion mainly via urine and bile ²². A 2026 biopharmaceutics review adds that a preliminary two-subject human intravenous pilot echoed the sub-30-minute half-life ³².

Two honest oddities. First, the PK-PD disconnect: a plasma half-life under 30 minutes sits awkwardly against biological effects reported to last hours to days in animal models, and no one has a validated explanation ³². Second, oral exposure: BPC-157 is repeatedly described as unusually stable in gastric juice ^25,32, and oral dosing was active in rodent GI and ligament models ^6,28, but systemic oral bioavailability in humans has never been measured, and the peptide lacks basic permeability characterization ³².

The gray market sells lyophilized vials for injection, oral capsules, and lately branded gummies ⁴². The research literature used different routes for different questions: intraperitoneal injection dominates the musculoskeletal work ^1,7; per-oral dosing (in drinking water) was reported active in ligament and GI models ^6,28; topical creams were used in burn and muscle models ^14,8; eye drops in the corneal model ¹⁹; and the human knee series used intra-articular injection ²³.

No route has established human efficacy, and no pharmaceutical-grade formulation exists for any route ³². FDA's immunogenicity concern is explicitly tied to certain routes of administration of compounded BPC-157 ³⁴. See the injectable-versus-oral comparison table for the route-by-route evidence.

There is no established human dose of BPC-157. No dose-finding study in humans has ever been published ³². What exists are animal study doses: the originating group's standard regimens are 10 ug/kg and 10 ng/kg body weight, usually intraperitoneal, once daily ^1,2; the ligament study added per-oral dosing at 0.16 ug/mL drinking water and topical 1 ug/g cream ⁶; the 2026 head-to-head study used 10 ug/kg/day intraperitoneally for four weeks ¹¹; the rabbit bone study used 10 ug/kg locally or intramuscularly ¹⁰.

Simple arithmetic shows why animal-to-human dose translation here is guesswork: nobody has published what a rodent intraperitoneal microgram-per-kilogram regimen corresponds to in a human by any route, because human bioavailability was never measured ³². The doses printed on gray-market vials and forum protocols are not derived from any published human study. Our dosing tools therefore do reconstitution arithmetic only, and label study doses by species.

What is reported: the originating group states no toxicity was observed in animal work and that an LD1 could not be reached, and describes the compound as safe in its (unpublished) IBD trials ²⁵. The 2025 systematic review found no adverse effects in preclinical safety studies and no adverse events in the small human pilots, and then stated the load-bearing fact plainly: no clinical safety data were found ^30,31.

What nobody has assessed: immunogenicity. FDA's stated concern is that compounded BPC-157 may pose immunogenicity risk for certain routes and carries peptide-impurity and API-characterization complexities, and that the agency lacks sufficient information to know whether the drug would cause harm when administered to humans ³⁴. Absence of reported harm in rodents and in fewer than 30 pilot subjects is not human safety evidence.

The practical risk on top of the biological unknowns is sourcing: BPC-157 reaches users through unregulated channels, and the systematic review flags unregulated manufacturing and contamination as real adverse-effect pathways ³⁰. There is no USP monograph, no pharmaceutical-grade formulation, and no validated quality standard for the vials actually being sold ³².

Formal interaction studies do not exist. The animal literature reports interactions with the nitric oxide system (L-arginine and L-NAME modified its effects in rat models) ²⁶, counteraction of corticosteroid-impaired repair ^2,9, and altered bleeding parameters alongside heparin, warfarin, and aspirin in rats ²¹. None of this has been characterized in humans.

Who has not been studied: pregnant or breastfeeding people, children, people with cancer or a cancer history (relevant because the proposed mechanism is pro-angiogenic ²⁰), people on anticoagulants, and people with immune conditions. That is not a list of established risks; it is a list of populations with zero data, plus FDA's unassessed-immunogenicity flag ³⁴. Tested athletes are a special case: any use violates WADA rules regardless of safety ⁴³.

The one well-documented stability property is chemical: BPC-157 is repeatedly described as stable in gastric juice, unusual for a peptide ^25,32. Beyond that, formulation science is missing: a 2026 review found no pharmaceutical-grade formulation has been developed or validated for any route, no BCS classification data, and no formal excipient compatibility studies ³².

Practical consequence: there is no validated storage or reconstitution standard for the research-market vials being sold. Handling practices circulating online are lab convention, not tested product science, and FDA's impurity and API-characterization concerns apply directly to this unregulated supply ³⁴.

Twelve questions, answered in 320 characters or fewer, every answer consistent with the graded evidence table above.

Every reference below was fetched and verified against its source on 2026-08-13/14: PubMed records via the NCBI E-utilities API, FDA pages and the July 2026 PCAC briefing document retrieved directly from fda.gov, the 2026 WADA Prohibited List PDF retrieved from wada-ama.org, trial records from the ClinicalTrials.gov v2 API, and chemical identity from PubChem. Study titles are reproduced verbatim. A machine-readable version of this list ships as the citation manifest for this page.